Youssra Salhi

Youssra Salhi

Auto-generated profile, based on publicly available information

Youssra Salhi


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2025 in Advances in Pharmacological and Pharmaceutical Sciences
Verified
Journal Article
Open access
CAChaimae Alla
Chaimae Alla
AAAmanat Ali
Amanat Ali
AMAfaf Mehiou
Afaf Mehiou
YSYoussra Salhi
Youssra Salhi
NBNourelhouda Bouanani
Nourelhouda Bouanani
AZAbderrahim Ziyyat
Abderrahim Ziyyat
The long-term pathological state known as metabolic syndrome is characterized by hypertension, insulin resistance diabetes, abdominal obesity, and hyperlipidemia. Seeking healthcare strategies with fewer side effects, such as herbal remedies, is preferable in terms of mitigating the negative consequences of synthetic medications. Ziziphus lotus (L.) (Rhamnaceae) or wild jujube,commonly known as “Sedra,” is one of the best choices as it contains a variety of phytochemicals and biologically active compounds. Several favonoids and stilbenes have been recognized as the primary bioactive components in wild jujube, including rutin, hyperin, isoquercitrin, and resveratrol. These polyphenols are pharmacologically active and have broad-spectrum beneficial effects for reducing the risk factors associated with metabolic syndrome. Tey exhibit antioxidant and anti-infammatory properties, regulate lipid metabolism, and possess antiobesity, antihypertensive, and antidiabetic characteristics. However, there are certain limitations to their therapeutic application, such as low bioavailability. Various strategies have been proposed to enhance their pharmacokinetic profile and therapeutic potential for future use. The main goal of this review is to explore the underlying mechanisms related to the therapeutic effects of wild jujube and its active compounds in the treatment and prevention of metabolic syndrome.